Second European endoscopy forum, Sintra, Portugal, 17-18 June, 1999: Twenty questions on the esophagogastric junction

Endoscopy

Volumn 32, Issue 5, 2000, Pages 411-418

  Axon, A ^a   Lambert, R ^b,e   Robaszkiewicz, M ^c   Rosch T ^f   Sonnenberg, A ^d  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d University of Texas Medical Branch School of Medicine   (United States)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; CARCINOGENESIS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DYSPLASIA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPY; ESOPHAGUS BIOPSY; GASTROESOPHAGEAL REFLUX; HUMAN; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

ADENOCARCINOMA; BARRETT ESOPHAGUS; COST-BENEFIT ANALYSIS; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY, DIGESTIVE SYSTEM; ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; GASTROESOPHAGEAL REFLUX; HUMANS; TREATMENT OUTCOME;

EID: 0034005854     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-8998     Document Type: Conference Paper

References (48)

1. Barrett NR. The lower oesophagus lined by columnar epithelium. Surgery 1957; 41: 881-894
2. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined Barrett's esophagus: comparison of population based clinical and autopsy findings. Gastroenterology 1990; 99: 918-922
3. Chalsani N, Woo JM, Hunter JG, Waring SP. Significance of intestinal metaplasia in different areas of the oesophagus including oesophagogastric junction. Dig Dis Sci 1997; 42: 603-607
4. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277-285
5. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus: functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg 1983; 118: 543-549
6. Kahrilas PJ. Anatomy and physiology of the gastroesophageal junction. Gastroenterol Clin North Am 1997; 3: 467-485
7. Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am 1997; 3: 613-634
8. Ormsby AH, Goldblum JR, Richter JE, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999; 30: 288-294
9. Spechler SJ. The columnar-lined esophagus: histology, terminology and clinical issues. Gastroenterol Clin North Am 1997; 26: 445-466
10. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117: 218-228
11. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315: 362-371
12. Van der Burgh A, Dees J, Hopp WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8
13. Wijnhoven BP, Siersema PD, Hop WC, et al. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity (Rotterdam Oesophageal Tumour Group). Br J Surg 1999; 86: 529-535
14. Wright TA. High-grade dysplasia in Barrett's oesophagus. Br J Surg 1997; 84: 760-766
15. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 86-91
16. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053
17. Dolan K, Sutton R, Walker SJ, et al. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer 1999; 80: 834-842
18. Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway, 1958-1992: incidence, time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997; 71: 340-344
19. National Cancer Institute. Surveillance, Epidemiology, and End Results. SEER*Stat for Windows 95/NT, Version 1.1: SEER cancer incidence public-use database, 1993-1995. Bethesda, MD: US Department of Health and Human Services, 1997
20. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107: 747-754
21. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990; 98: 654-661
22. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997; 92: 27-31
23. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease Gut 1998; 43: 327-333
24. El-Serag HB, Sonnenberg A. Associations among different forms of gastroesophageal reflux disease. Gut 1997; 41: 594-599
25. Galmiche JP, Janssens J. The pathophysiology of gastro-oesophageal reflux disease: an overview. Scand J Gastroenterol 1995; 30 (Suppl 211): 7-18
26. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
27. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-956
28. Sonnenberg A, El-Serag HB. Epidemiology of gastroesophageal reflux disease In: Büchler MW. Farthmann EH Progress in Surgery, vol. 23Basle: Karger 1997: 20-36
29. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-1268
30. Burtin P, Napoleon B, Palazzo L, et al. Interobserver agreement in endoscopie ultrasonography staging of esophageal and cardia cancer. Gastrointest Endosc 1996; 43: 20-24
31. Canto M. Vital staining and Barrett's esophagus. Gastrointest Endosc 1999; 49: S12-6
32. Eloubeidi MA, Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999; 94: 937-943
33. Ellis KK, Oehlke M, Helfand M, Lieberman D. Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management? Am J Gastroenterol 1997; 92: 1472-1474
34. Ellis FH, Loda M. Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett' s adenocarcinoma. Dis Esophagus 1997; 10: 165-171
35. Murata Y. The role of endoscopic ultrasonography for gastric cancer in the cardiac area [in Japanese]. Nippon Geka Gakkai Zasshi 1998; 99: 564-568
36. Tytgat GN. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any value? Endoscopy 1995; 27: 19-26
37. Tytgat GN. Endoscopic features of the columnar-lined esophagus. Gastroenterol Clin North Am 1997; 3: 507-517
38. Fennerty MB. Perspectives on endoscopic eradication of Barrett's esophagus: who are appropriate candidates and what is the best method? Gastrointest Endosc 1999; 49 (3): 24-28
39. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114: 448-455
40. Lightdale CJ. Ablation therapy for Barrett's esophagus: is it time to choose our weapons? Gastrointest Endosc 1999; 49: 122-125
41. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1-7
42. Van den Boogert J, van Hillegersberg R, Siersema PD, et al. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol 1999; 94: 1153-1160
43. Van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid-term results. Gut 1998; 43: 747-751
44. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670-680
45. Sonnenberg A. Esophageal diseases. In: Everhart JEDigestive diseases in the United States: epidemiology and impact (US Department of Health and Human Services, NIH publication no. 94-1447).Washington, DC: US Government Printing Office 1994: 299-356
46. Sonnenberg A, El-Serag HB. Economic aspects of endoscopie screening for intestinal precancerous conditions. Gastrointest Endosc Clin North Am 1997; 7: 165-184
47. Sonnenberg A, Delco F, El-Serag HB. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis. Dig Dis Sci 1998; 43: 1001-1008
48. Wright TA, Gray MR, Morris AI, et al. Cost-effectiveness of detecting Barrett's cancer. Gut 1996; 39: 574-579